Publication:
RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models

dc.contributor.authorSuphalak Khachonkhamen_US
dc.contributor.authorElisabeth Maraen_US
dc.contributor.authorSylvia Gruberen_US
dc.contributor.authorRafael Preueren_US
dc.contributor.authorPeter Kuessen_US
dc.contributor.authorWolfgang Dörren_US
dc.contributor.authorDietmar Georgen_US
dc.contributor.authorMonika Clausenen_US
dc.contributor.otherMedAustron, Austriaen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMedizinische Universitat Wienen_US
dc.contributor.otherUniversity of Applied Sciences Wieneren_US
dc.date.accessioned2020-10-05T03:57:54Z
dc.date.available2020-10-05T03:57:54Z
dc.date.issued2020-09-01en_US
dc.description.abstract© 2020 Associazione Italiana di Fisica Medica Purpose: In-vitro radiobiological studies are essential for modelling the relative biological effectiveness (RBE) in proton therapy. The purpose of this study was to experimentally determine the RBE values in proton beams along the beam path for human prostate carcinoma cells (Du-145). RBE-dose and RBE-LETd (dose-averaged linear energy transfer) dependencies were investigated and three phenomenological RBE models, i.e. McNamara, Rørvik and Wilkens were benchmarked for this cell line. Methods: Cells were placed at multiple positions along the beam path, employing an in-house developed solid phantom. The experimental setup reflected the clinical prostate treatment scenario in terms of field size, depth, and required proton energies (127.2–180.1 MeV) and the physical doses from 0.5 to 6 Gy were delivered. The reference irradiation was performed with 200 kV X-ray beams. Respective (α/β) values were determined using the linear quadratic model and LETd was derived from the treatment planning system at the exact location of cells. Results and Conclusion: Independent of the cell survival level, all experimental RBE values were consistently higher in the target than the generic clinical RBE value of 1.1; with the lowest RBE value of 1.28 obtained at the beginning of the SOBP. A systematic RBE decrease with increasing dose was observed for the investigated dose range. The RBE values from all three applied models were considerably smaller than the experimental values. A clear increase of experimental RBE values with LETd parameter suggests that proton LET must be taken into consideration for this low (α/β) tissue.en_US
dc.identifier.citationPhysica Medica. Vol.77, (2020), 187-193en_US
dc.identifier.doi10.1016/j.ejmp.2020.08.012en_US
dc.identifier.issn1724191Xen_US
dc.identifier.issn11201797en_US
dc.identifier.other2-s2.0-85090054600en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/58966
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090054600&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleRBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological modelsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090054600&origin=inwarden_US

Files

Collections